Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
L04 AA10
|
| gptkbp:available_on |
generic drug
|
| gptkbp:brand |
Rapamune
|
| gptkbp:casnumber |
53123-88-9
|
| gptkbp:chemical_formula |
C51 H79 NO13
|
| gptkbp:clinical_trial |
Phase III trials
Phase I trials Phase II trials |
| gptkbp:composed_by |
gptkb:chemical_compound
fermentation |
| gptkbp:contraindication |
liver disease
hypersensitivity to sirolimus concurrent use of strong CYP3 A4 inhibitors |
| gptkbp:developed_by |
Streptomyces hygroscopicus
|
| gptkbp:discovered_by |
gptkb:1972
|
| gptkbp:dosage_form |
gptkb:Software_Solutions
gptkb:tablet injection |
| gptkbp:formulation |
oral solution
intravenous injection |
| https://www.w3.org/2000/01/rdf-schema#label |
sirolimus
|
| gptkbp:interacts_with |
gptkb:fruit
gptkb:HIV_protease_inhibitors antibiotics certain antifungals |
| gptkbp:invention |
patented
off patent |
| gptkbp:lifespan |
62 hours
|
| gptkbp:mechanism_of_action |
m TOR inhibitor
|
| gptkbp:metabolism |
gptkb:CYP3_A4
|
| gptkbp:pharmacokinetics |
oral bioavailability 14-30%
|
| gptkbp:provides_guidance_on |
Cancer treatment guidelines
Kidney transplant guidelines Lung transplant guidelines Lymphangioleiomyomatosis guidelines |
| gptkbp:research_areas |
gptkb:cancer_treatment
metabolic disorders autoimmune diseases cardiovascular diseases |
| gptkbp:safety |
Category C (pregnancy)
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea vomiting diarrhea rash high cholesterol thrombocytopenia hyperlipidemia increased risk of infection kidney problems stomatitis lung problems |
| gptkbp:storage |
room temperature
|
| gptkbp:used_for |
preventing organ transplant rejection
treating lymphangioleiomyomatosis |
| gptkbp:bfsParent |
gptkb:Eluvia_Drug-Eluting_Stent
|
| gptkbp:bfsLayer |
5
|